Glenmark bags another FDA approval
09 November 2015 | News | By BioSpectrum Bureau
Glenmark bags another FDA approval
Glenmark's drug is the therapeutic equivalent of Lotrisone Cream
Glenmark Pharmaceuticals USA (Glenmark) has been granted final approval by the United States Food and Drug Administration (US FDA) for Clotrimazole and Betamethasone Dipropionate Cream USP, 1 percent|0.05 percent.
The drug is the therapeutic equivalent of Lotrisone Cream USP, 1 percent|0.05 percent of Merck, Sharp and Dohme Corporation.
According to IMS Health sales data for the 12 month period ending September 2015, the Lotrisone Cream USP, 1 percent|0.05 percent market achieved annual sales of approximately $82.4 million.
